Literature DB >> 11146103

Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus.

T Ohnuma1, S Tessler, H Arai, R L Faull, P J McKenna, P C Emson.   

Abstract

A disturbance in glutamatergic transmission has been suggested to contribute to the pathophysiology of schizophrenia and recent studies on ionotropic glutamate receptors are consistent with altered glutamatergic function in the hippocampus of schizophrenics. In order to investigate this hypothesis further, the expression of two 'glutamatergic' markers, the mRNAs of metabotropic glutamate receptor 5 (mGluR5) and human excitatory amino acid transporter (EAAT2) were compared in the hippocampus of control subjects and schizophrenics. We examined the regional/cellular mRNA expression of mGluR5 and EAAT2 in postmortem hippocampal sections from schizophrenics and control subjects, using in situ hybridization. Regions of interests were dentate gyrus, cornu ammonis 4, 3, 1 and parahippocampal gyrus. The regional/cellular mGluR5 mRNA content was not different between the two groups. The cellular EAAT2 mRNA content was significantly decreased in schizophrenic parahippocampal gyrus, but not in other hippocampal regions. Furthermore, only in the parahippocampal gyrus, schizophrenics had a significantly increased mGluR5/EAAT2 ratio at both the regional and cellular mRNA level. The results suggest that a disturbance of glutamatergic neurotransmission in schizophrenia was not apparent using these indices in the hippocampus, but 'hypo-glutamatergic' neurotransmission may be present in the schizophrenic parahippocampal gyrus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11146103     DOI: 10.1016/s0169-328x(00)00222-9

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  25 in total

Review 1.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

2.  Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.

Authors:  Michael F Egan; Richard E Straub; Terry E Goldberg; Imtiaz Yakub; Joseph H Callicott; Ahmad R Hariri; Venkata S Mattay; Alessandro Bertolino; Thomas M Hyde; Cynthia Shannon-Weickert; Mayada Akil; Jeremy Crook; Radha Krishna Vakkalanka; Rishi Balkissoon; Richard A Gibbs; Joel E Kleinman; Daniel R Weinberger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

Review 3.  Translational potential of astrocytes in brain disorders.

Authors:  Alexei Verkhratsky; Luca Steardo; Vladimir Parpura; Vedrana Montana
Journal:  Prog Neurobiol       Date:  2015-09-16       Impact factor: 11.685

Review 4.  Imaging genomics and response to treatment with antipsychotics in schizophrenia.

Authors:  Giuseppe Blasi; Alessandro Bertolino
Journal:  NeuroRx       Date:  2006-01

5.  White Matter Microstructure in Bipolar Disorder Is Influenced by the Interaction between a Glutamate Transporter EAAT1 Gene Variant and Early Stress.

Authors:  Sara Poletti; Irene Bollettini; Cristina Lorenzi; Alice Vitali; Silvia Brioschi; Alessandro Serretti; Cristina Colombo; Francesco Benedetti
Journal:  Mol Neurobiol       Date:  2018-05-22       Impact factor: 5.590

6.  Abnormal partitioning of hexokinase 1 suggests disruption of a glutamate transport protein complex in schizophrenia.

Authors:  Dan Shan; Daniel Mount; Stephen Moore; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2014-02-21       Impact factor: 4.939

Review 7.  GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism.

Authors:  S Hossein Fatemi; Timothy D Folsom
Journal:  Schizophr Res       Date:  2014-11-26       Impact factor: 4.939

8.  Changes in region- and cell type-specific expression patterns of neutral amino acid transporter 1 (ASCT-1) in the anterior cingulate cortex and hippocampus in schizophrenia, bipolar disorder and major depression.

Authors:  S Weis; I C Llenos; J R Dulay; N Verma; S Sabunciyan; R H Yolken
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

9.  Screening cascade and development of potential Positron Emission Tomography radiotracers for mGluR5: in vitro and in vivo characterization.

Authors:  Shil Patel; Obinna Ndubizu; Terence Hamill; A Chaudhary; H Donald Burns; R Hargreaves; Raymond E Gibson
Journal:  Mol Imaging Biol       Date:  2005 Jul-Aug       Impact factor: 3.488

Review 10.  Metabotropic glutamate receptor 5 - a promising target in drug development and neuroimaging.

Authors:  Rajapillai L I Pillai; Dnyanesh N Tipre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-07       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.